Elevated Lp(a) is a unique and genetically determined condition that can increase risk for ASCVD—in patients younger than you might expect^1,2,8-11

Watch the video to see how Lp(a) testing can uncover a potential CV risk in patients with premature ASCVD (age <55 years in men, age <65 years in women)—and their family members.^7,9

Despite its clinical significance, Lp(a) levels are often not measured as part of a standard CV risk assessment^7,12,13

^†Clinical relevance is unknown.

^‡Atherogenicity was defined as the difference in coronary heart disease (CHD) risk per unit difference in Lp(a) or LDL particle number (molar concentration). This study was based on the UK Biobank population (>502,000 UK residents) who were predominately of European ancestry. The generalizability of the findings was tested in a replication cohort: the CARDIoGRAMplusC4D (Coronary ARtery DIsease Genome wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease Genetics) data set. Study did not differentiate between subjects with or without CHD at baseline. Analysis focused on the ApoB component of Lp(a).¹⁵

• Lp(a) levels are ~90% genetically determined, typically established by 5 years of age, relatively consistent over time, and generally not affected by diet or lifestyle^1,2,9,16

• In one study, the higher a person's Lp(a) level, the higher their risk for a lifetime CV event¹⁶

• The CV risk from elevated Lp(a) is independent of other risk factors^2,5,7,17

Uncovering elevated Lp(a) can provide a deeper understanding of cardiovascular risk for your patients with premature ASCVD—and for their family members^7,9

ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular disease; LDL, low-density lipoprotein; Lp(a), Lipoprotein (a).